本文由小咖机器人翻译整理

期刊来源：Lancet

原文链接：https://doi.org/10.1016/S0140-6736(23)02756-3

摘要内容如下：

射血分数正常的心力衰竭（HFPEF）在临床实践中得到越来越多的认可和诊断，这一趋势是由人口老龄化和肥胖和糖尿病等合并症的增加所推动的。HFPEF至少占所有心力衰竭病例的一半，被认为是一种复杂的临床综合征。由于其不同的病理生理学、不同的流行病学模式以及不断发展的诊断和治疗方法，其诊断和治疗具有挑战性。本次研讨会综合了关于HFPEF的最新见解，整合了近期临床试验、流行病学研究和最新指南建议的结果。我们深入研究了HFPEF的定义、发病机制、流行病学、诊断标准和治疗策略（非药理学和药理学）。我们强调正在进行的临床试验和该领域的未来发展。具体来说，该研讨会为初级保健从业人员、全科医生和不专门研究心力衰竭的心脏病学家提供了实用指导，简化了HFPEF诊断和管理的复杂性。我们提供了实用的循证建议，强调了解决合并症和整合最新药物治疗（如SGLT2抑制剂）的重要性。

英文原文如下：

Abstracts

Heart failure with preserved ejection fraction (HFpEF) is increasingly recognised and diagnosed in clinical practice, a trend driven by an ageing population and a rise in contributing comorbidities, such as obesity and diabetes. Representing at least half of all heart failure cases, HFpEF is recognised as a complex clinical syndrome. Its diagnosis and management are challenging due to its diverse pathophysiology, varied epidemiological patterns, and evolving diagnostic and treatment approaches. This Seminar synthesises the latest insights on HFpEF, integrating findings from recent clinical trials, epidemiological research, and the latest guideline recommendations. We delve into the definition, pathogenesis, epidemiology, diagnostic criteria, and management strategies (non-pharmacological and pharmacological) for HFpEF. We highlight ongoing clinical trials and future developments in the field. Specifically, this Seminar offers practical guidance tailored for primary care practitioners, generalists, and cardiologists who do not specialise in heart failure, simplifying the complexities in the diagnosis and management of HFpEF. We provide practical, evidence-based recommendations, emphasising the importance of addressing comorbidities and integrating the latest pharmacological treatments, such as SGLT2 inhibitors.

-----------分割线---------

点击链接：https://www.mediecogroup.com/community/user/vip/categories/ ，成为医咖会员，获取12项专属权益。

现在购买可享受最大优惠（买一年送三个月，买两年送一年），2024年2月10日起将不再享有该优惠。